Liberation Bioindustries
its 600,000-liter Richmond, Indiana precision-fermentation facility (roughly 75% complete) paused construction again in June 2026 for lack of funding, even as CEO Etan Bendheim reports customer interest exceeding 200% of the facility's planned capacity — a stark illustration of the capacity-versus-capital gap this brok…
- Country
- United States
contract-biomanufacturing
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| market-access-commercial | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Fermentation-capacity brokerage | market-access-commercial | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.